Rabien Anja, Stephan Carsten, Kilic Ergin, Weichert Wilko, Kristiansen Glen, Miller Kurt, Jung Klaus, Erbersdobler Andreas
Department of Urology, Research Division, Charité - Universitätsmedizin Berlin, Charitéplatz 1, Berlin 10117, Germany.
J Transl Med. 2013 Oct 16;11:258. doi: 10.1186/1479-5876-11-258.
Matrix metalloproteinases can promote invasion and metastasis, which are very frequent in renal cell carcinoma even at the time of diagnosis. Knowing the reversion-inducing cysteine-rich protein with Kazal motifs (RECK) as an inhibitor of matrix metalloproteinases and the extracellular matrix metalloproteinase inducer (EMMPRIN) protein as inducer, we aimed to determine their expression, localization and possible antagonistic action in the pathogenesis and progression of renal cell tumors in a retrospective study.
Tumor and adjacent normal tissues of 395 nephrectomized patients were immunostained for RECK and EMMPRIN on a tissue microarray.
RECK strongly decreased in renal cell carcinoma compared to normal counterparts (Wilcoxon signed rank test, P<0.001), and it discriminated tumor entities showing the highest expression in oncocytomas. EMMPRIN, however, could be significantly correlated to pT stage and Fuhrman grading (Spearman's correlation coefficient rs=0.289 and rs=0.382, respectively). Higher expression of EMMPRIN was associated with decreased overall survival in Kaplan-Meier analysis (P<0.001), and the EMMPRIN level could independently predict survival for cases without metastasis and involvement of lymph nodes. Decreased RECK expression was confirmed by Western blotting in tissue of eight normal/tumor matches of patients after radical nephrectomy, whereas the EMMPRIN pattern appeared to be heterogeneous.
We propose RECK down regulation in renal cell carcinoma to be an early event that facilitates tumor formation and progression. EMMPRIN, however, as a prognostic tumor marker, increases only when aggressiveness is proceeding and could add an additional step to invasive properties of renal cell carcinoma.
基质金属蛋白酶可促进侵袭和转移,这在肾细胞癌中很常见,甚至在诊断时就已出现。已知具有Kazal基序的富含半胱氨酸的逆转诱导蛋白(RECK)是基质金属蛋白酶的抑制剂,而细胞外基质金属蛋白酶诱导因子(EMMPRIN)蛋白是诱导剂,我们旨在通过一项回顾性研究确定它们在肾细胞肿瘤的发病机制和进展中的表达、定位及可能的拮抗作用。
在组织芯片上对395例接受肾切除术患者的肿瘤及相邻正常组织进行RECK和EMMPRIN免疫染色。
与正常组织相比,肾细胞癌中RECK显著降低(Wilcoxon符号秩检验,P<0.001),且其在嗜酸细胞瘤中表达最高,可区分肿瘤实体。然而,EMMPRIN与pT分期和Fuhrman分级显著相关(Spearman相关系数rs分别为0.289和0.382)。在Kaplan-Meier分析中,EMMPRIN高表达与总生存率降低相关(P<0.001),且EMMPRIN水平可独立预测无转移和无淋巴结受累病例的生存率。根治性肾切除术后8例患者的正常/肿瘤配对组织的Western印迹证实了RECK表达降低,而EMMPRIN模式似乎具有异质性。
我们认为肾细胞癌中RECK下调是促进肿瘤形成和进展的早期事件。然而,EMMPRIN作为一种预后肿瘤标志物,仅在侵袭性进展时增加,可能会增加肾细胞癌侵袭性的额外步骤。